Modality
Radioligand
MOA
PD-1i
Target
DLL3
Pathway
Lipid Met
CTCL
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
~Mar 2024
→ ~Jun 2025
Phase 2
Sep 2025
→ Sep 2030
Phase 2Current
NCT04809843
2,533 pts·CTCL
2025-09→2030-09·Recruiting
2,533 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-194.5y awayPh3 Readout· CTCL
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-09-19 · 4.5y away
CTCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04809843 | Phase 2/3 | CTCL | Recruiting | 2533 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| RCU-6379 | Arcus Bio | Phase 1/2 | DLL3 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R |